Stock screenerAll disclosures →
EDGAR →
INKT
Conviction 35HealthcareScan · Fri, Jun 26, 2026Inverted hammer
INKT$11.47+1.41%
ResistanceSupportVol 14Insider sell2
Vol MA14 27.15K
Mar 27Apr 15May 4May 20Jun 9Jun 26
Price11.47
Change+1.41%
Gap+3.36%
Rel volume0.23×
Avg volume33.66K
Avg $ vol410.12K
SMA 2012.09
SMA 5011.65
SMA 20012.12
Price vs 50-1.51%
Price vs 200-5.34%
MA stackbearish
50/200 cross—
Supertrendup · 9.84
RSI (14)47
MACD hist-0.10
MACD crossbear · 2d
Stoch %K / %D26 / 29
ADX (14)19
+DI / −DI15 / 16
RSI divergence—
MACD divergence—
ATR %+7.35%
ADR %7.29%
52w high64.17
52w low6.98
From 52w high-82.13%
Above 52w low+64.33%
New 52w highNo
SqueezeOn · 4d
Bollinger width13.08%
%B0.11
Donchian pos18.25%
Donchian high13.40
Donchian low11.04
AVWAP (52w high)38.60
vs AVWAP high-70.29%
AVWAP (52w low)38.60
vs AVWAP low-70.28%
OBV trendUp
Chaikin MF (20)0.02
Today vs 20d0.23×
Avg vol (14d)27.14K
Avg vol (20d)33.66K
Avg $ vol (20d)410.12K
Market cap—
RS 3m (vs SPY)+12.15%
RS 6m (vs SPY)-10.23%
RS line new highNo
Trend template2/8
Technical rank28.2
1 week-5.52%
1 month+12.67%
3 months+19.11%
6 months-4.73%
1 year+51.12%
YTD+3.15%
P/E-4.54
P/B-4.47
P/S—
P/FCF-9.45
EPS-2.93
Div yield—
ROE98.49%
ROA-120.40%
Debt/Eq—
Current1.38
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth-15.85%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value47.17M
Revenue—
Net income-2.74M
Gross profit—
Free cash flow-6M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out4.98M
Employees15
ListedFri, Oct 15, 2021
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction35 / 100
Pattern quality—
Tech rank28.2 / 100
Group rank50 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmInverted hammer
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in INKT
No recent disclosed trades by Congress in INKT. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in INKT · 7 buys · 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Ryan Barbara Director · Common Stock · 2026-06-04 | Sell | 1K | $13K | 2026-06-04 | 2026-06-05 |
Ryan Barbara Director · Common Stock · 2026-06-04 | Sell | 500 | $6K | 2026-06-04 | 2026-06-05 |
Behner Peter Director · Common Stock · 2026-06-01 | Grant | 1.31K | $16K | 2026-06-01 | 2026-06-02 |
Holcomb John Bradley Director · Common Stock · 2026-06-01 | Grant | 1.09K | $14K | 2026-06-01 | 2026-06-02 |
Ryan Barbara Director · Common Stock · 2026-06-01 | Grant | 1.43K | $18K | 2026-06-01 | 2026-06-02 |
Corvese Brian Director · Common Stock · 2026-06-01 | Grant | 1.44K | $18K | 2026-06-01 | 2026-06-02 |
WIINBERG ULF Director · Common Stock · 2026-06-01 | Grant | 1.13K | $14K | 2026-06-01 | 2026-06-02 |
WIINBERG ULF Director · Common Stock · 2026-03-02 | Other | — | — | 2026-03-02 | 2026-06-02 |
WIINBERG ULF Director · Common Stock · 2026-03-02 | Grant | 1.28K | $14K | 2026-03-02 | 2026-06-02 |
Ryan Barbara Director · Common Stock · 2026-03-02 | Grant | 1.63K | $18K | 2026-03-02 | 2026-06-02 |
SEC filings
EDGAR filings in INKT · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.